IN2014DN00200A - - Google Patents

Info

Publication number
IN2014DN00200A
IN2014DN00200A IN200DEN2014A IN2014DN00200A IN 2014DN00200 A IN2014DN00200 A IN 2014DN00200A IN 200DEN2014 A IN200DEN2014 A IN 200DEN2014A IN 2014DN00200 A IN2014DN00200 A IN 2014DN00200A
Authority
IN
India
Prior art keywords
riluzole
subject
methods
reducing
auc24h
Prior art date
Application number
Inventor
Jesse Cedarbaum
John Mao
Fady Malik
Andrew A Wolff
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of IN2014DN00200A publication Critical patent/IN2014DN00200A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided is a method for treating ALS in a subject comprising administering to the subject a therapeutically effective amount of riluzole and a therapeutically effective amount of CK 2017357. Also provided are methods of reducing the variability of riluzole exposure (e.g. Cmax and/or AUC24h) in a subject methods of reducing the variability of riluzole exposure (e.g. Cmax and/or AUC24h) between two or more subjects methods of decreasing the total daily dose of riluzole in a subject methods of increasing the half life of riluzole in a subject methods for decreasing the frequency of riluzole dosing in the subject and methods for reducing the incidence and/or severity of adverse events in a subject treated with riluzole.
IN200DEN2014 2011-07-13 2012-07-12 IN2014DN00200A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161507381P 2011-07-13 2011-07-13
US201161544533P 2011-10-07 2011-10-07
US201261637770P 2012-04-24 2012-04-24
US201261637759P 2012-04-24 2012-04-24
US201261646699P 2012-05-14 2012-05-14
PCT/US2012/046523 WO2013010015A2 (en) 2011-07-13 2012-07-12 Combination als therapy

Publications (1)

Publication Number Publication Date
IN2014DN00200A true IN2014DN00200A (en) 2015-06-05

Family

ID=47506929

Family Applications (1)

Application Number Title Priority Date Filing Date
IN200DEN2014 IN2014DN00200A (en) 2011-07-13 2012-07-12

Country Status (15)

Country Link
US (1) US10272082B2 (en)
EP (1) EP2731611B1 (en)
JP (2) JP6145946B2 (en)
KR (1) KR101951220B1 (en)
CN (2) CN104039148A (en)
AU (2) AU2012281042B2 (en)
BR (1) BR112014000742A2 (en)
CA (1) CA2849213A1 (en)
EA (2) EA201791043A1 (en)
HK (1) HK1197178A1 (en)
IL (1) IL230391B (en)
IN (1) IN2014DN00200A (en)
SG (1) SG10201605707UA (en)
WO (1) WO2013010015A2 (en)
ZA (1) ZA201400236B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
WO2015063318A1 (en) * 2013-11-04 2015-05-07 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis
RS63018B1 (en) * 2014-04-29 2022-04-29 Cytokinetics Inc Methods of reducing decline in vital capacity
WO2016081466A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
CA2967662A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual formulation of riluzole
EP3072513A1 (en) * 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
JP7250312B2 (en) 2016-03-25 2023-04-03 エービー サイエンス Use of macitinib for the treatment of subpopulations of patients with amyotrophic lateral sclerosis
EP4031135A4 (en) * 2019-09-20 2023-10-18 Icahn School of Medicine at Mount Sinai Controlled release formulations of riluzole and their uses

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
BE788065A (en) 1971-08-26 1973-02-26 Degussa NEW AZA-BENZIMIDAZOLES AND PROCESS FOR THEIR PREPARATION
IT1156732B (en) 1978-05-10 1987-02-04 Roussel Maestretti Spa SUBSTITUTED DERIVATIVES OF 1,3-DIHYDROIMIDAZO (4,5-B) PIRIDIN-2-ONE AND RELATED PRODUCTION PROCESS
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0641135A (en) 1992-07-21 1994-02-15 Nippon Soda Co Ltd Imidazopteridine derivative and its production
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
PL345906A1 (en) 1998-06-04 2002-01-14 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PT1218382E (en) 1999-10-08 2004-06-30 Gruenenthal Gmbh IMIDAZO-3-IL-AMINE BICYCLE DERIVATIVES
BR0014817A (en) 1999-10-08 2002-06-18 Gruenenthal Gmbh Imidazo-5-yl-bicyclic amines, medicines that contain them, their use for the preparation of medicines and procedure for their preparation
DE10050663A1 (en) 2000-10-13 2002-04-18 Gruenenthal Gmbh Use of amino-substituted imidazo(1,2-a)pyridine, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine derivatives as NO synthase inhibitors, e.g. in treatment of migraine and neurodegenerative diseases
US20040235801A1 (en) 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
US20030083318A1 (en) * 2001-10-25 2003-05-01 Jean-Pierre Julien Therapy for neurodegenerative diseases
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
AU2003294249A1 (en) 2002-11-08 2004-06-03 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن CGRP receptor antagonists
JP4705912B2 (en) 2003-06-26 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Benzodiazepine CGRP receptor antagonist
WO2005002520A2 (en) 2003-07-01 2005-01-13 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1694323A4 (en) 2003-12-19 2009-05-13 Elixir Pharmaceuticals Inc Methods of treating a disorder
EP1715855A4 (en) 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc Anti-viral therapeutics
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006036883A2 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CN101189238A (en) 2005-02-16 2008-05-28 先灵公司 Piperazine-piperidines with CXCR3 antagonist activity
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP2009536620A (en) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド Pharmaceutical combination
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US20100173930A1 (en) 2006-08-01 2010-07-08 Alex Muci Certain Chemical Entities, Compositions and Methods
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
ES2558517T3 (en) * 2006-08-02 2016-02-04 Cytokinetics, Inc. Certain chemical entities, compositions and methods comprising imidazopyrimidines
SI2583970T1 (en) * 2006-08-02 2016-03-31 Cytokinetics, Inc. Certain chemical entities, compositions and methods comprising imidazopyrimidines
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
ES2631003T3 (en) 2006-10-19 2017-08-25 Signal Pharmaceuticals, Llc Heteroaryl compounds, their compositions and methods of treatment with them
CL2007002994A1 (en) 2006-10-19 2008-02-08 Wyeth Corp HETEROCICLIC DERIVATIVE COMPOUNDS CONTAINING SULFAMOIL, INHIBITORS OF HSP90; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER, SUCH AS CANCER OF BREAST, COLON AND PROSTATE, BETWEEN OTHERS.
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
CN101663279A (en) 2007-01-19 2010-03-03 阿迪生物科学公司 inhibitors of mek
US7851484B2 (en) 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP2018854A1 (en) 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
BRPI0907502A2 (en) 2008-02-04 2019-01-15 Cytokinetics Inc at least one chemical entity, composition, and methods for treating a patient having a condition, for enhancing skeletal muscle function or activity, for enhancing skeletal muscle efficiency, for increasing the time of rapid skeletal muscle fiber fatigue, for sensitize a fast skeletal muscle fiber to produce strength in response to low calcium ion concentrations and to increase skeletal muscle fatigue time
US7998976B2 (en) 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
ES2554375T3 (en) 2008-11-25 2015-12-18 University Of Rochester MLK Inhibitors and Methods of Use
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
CN102802418A (en) * 2009-06-19 2012-11-28 诺普神经科学股份有限公司 Compositions and methods for treating amyotrophic lateral sclerosis
US20150065525A1 (en) 2012-04-02 2015-03-05 Cytokinetics, Inc. Methods for improving diaphragm function
EA032480B1 (en) 2012-04-11 2019-06-28 Сайтокинетикс, Инк. Methods for improving resistance to skeletal muscle fatigue
RS63018B1 (en) 2014-04-29 2022-04-29 Cytokinetics Inc Methods of reducing decline in vital capacity

Also Published As

Publication number Publication date
AU2012281042A1 (en) 2014-01-30
CA2849213A1 (en) 2013-01-17
EA028060B1 (en) 2017-10-31
US10272082B2 (en) 2019-04-30
JP2017128610A (en) 2017-07-27
AU2016244263A1 (en) 2016-11-03
HK1197178A1 (en) 2015-01-09
NZ619924A (en) 2016-02-26
CN109316480A (en) 2019-02-12
CN104039148A (en) 2014-09-10
BR112014000742A2 (en) 2016-08-23
EP2731611A4 (en) 2015-02-18
WO2013010015A3 (en) 2014-05-15
EA201490011A1 (en) 2014-08-29
EP2731611A2 (en) 2014-05-21
JP6145946B2 (en) 2017-06-14
EP2731611B1 (en) 2019-09-18
AU2012281042B2 (en) 2016-07-14
KR20140074270A (en) 2014-06-17
US20140243344A1 (en) 2014-08-28
KR101951220B1 (en) 2019-02-22
EA201791043A1 (en) 2017-09-29
WO2013010015A2 (en) 2013-01-17
ZA201400236B (en) 2014-10-29
JP2014520856A (en) 2014-08-25
SG10201605707UA (en) 2016-09-29
IL230391B (en) 2019-03-31

Similar Documents

Publication Publication Date Title
IN2014DN00200A (en)
MX365950B (en) Pyridazinone compounds and methods for the treatment of cystic fibrosis.
MY196418A (en) Therapeutically Active Compounds and Their Methods of use
GB201016812D0 (en) Method and apparatus for treating respiratory diesease
WO2012093258A3 (en) Irf5- related treatment and screening
MX2014004548A (en) Methods of treating pediatric patients using dexmedetomidine.
MX350666B (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia.
TN2015000027A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2014000515A (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers.
EA201490614A1 (en) TREATMENT OF DISEASES AND DISTURBANCES CAUSED BY ACTIVITY OF NF-kB TRANSCRIPTION FACTOR
MX2015003035A (en) Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade.
MX2019001977A (en) Methods and compositions for treating multiple sclerosis and related disorders.
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
MX2013008715A (en) Use of (s) - esmolol for controlling venous irritation associated with the treatment of a cardiac disorder.
MX2016000220A (en) Regulation of glucose metabolism using anti-cgrp antibodies.
CA2866819C (en) Method for treating inflammation
NZ597115A (en) Method of treating age related disorders with fujimycin
MX2010013790A (en) Compostions and methods for treating corneal inflammation.
MX2014013503A (en) Method for inducing udp-glucuronosyltransferase activity using pterostilbene.
WO2008129239A3 (en) Use of agents that inhibit homologous recombination for the treatment of cancer
MX359171B (en) Treatment of type i and type ii diabetes.
UA67100U (en) Method for treating anterior endogenous uveitis
MX2022002947A (en) Avocatin b for the treatment of diseases and conditions.
WO2011139368A3 (en) Methods of treatment of inflammatory diseases
IN2014DN05769A (en)